title: Chemopreventive efficacy of naringenin-loaded nanoparticles in 7,12-dimethylbenz(a)anthracene induced experimental oral carcinogenesis.
abstract: Nanochemoprevention has been introduced recently as a novel approach for improving phytochemicals bioavailability and anti-tumor effect. The present study is designed to evaluate the chemopreventive efficacy of prepared naringenin-loaded nanoparticles (NARNPs) relative to efficacy of free naringenin (NAR) against 7,12-dimethyl benz(a)anthracene (DMBA)-induced oral carcinogenesis by evaluating the status of lipid peroxidation, antioxidants and immunoexpression patterns of proliferating cell nuclear antigen (PCNA) and p53 proteins. Transmission electron microscope (TEM) and dynamic light scattering (DLS) investigations have confirmed a narrow size distribution of the prepared nanoparticles (40-90 nm) with ~88 % encapsulation efficiency. Oral squamous cell carcinoma (OSCC) was developed in the buccal pouch of golden Syrian hamsters by painting with 0.5 % DMBA in liquid paraffin three times a week for 14 weeks. DMBA painted animals revealed the morphological changes, hyperplasia, dysplasia and well-differentiated squamous cell carcinoma. Moreover, the status of lipid peroxidation, antioxidants and immunoexpression of PCNA and p53 were significantly altered during DMBA-induced oral carcinogenesis. Oral administration of NARNPs (50 mg NAR/kg body weight/day) to DMBA-treated animals completely prevented the tumor formation as compared to the free NAR and significantly reduced the degree of histological lesions, in addition to restoration of the status of biochemical and molecular markers during oral carcinogenesis. In addition, NARNPs have more potent anti-lipid peroxidative, antiproliferative effect and antioxidant potentials compared to free NAR in DMBA-induced oral carcinogenesis. In conclusion, the present study suggests that NARNPs could be a potentially useful drug carrier system for targeted delivery of naringenin for cancer chemoprevention.
authors.affiliation: Department of Physics, Annamalai University, Annamalainagar, 608 002, Tamilnadu, India.
authors.forename: Nechikkad
authors.initials: N
authors.lastname: Sulfikkarali
authors.forename: Narendran
authors.initials: N
authors.lastname: Krishnakumar
authors.forename: Shanmugam
authors.initials: S
authors.lastname: Manoharan
authors.forename: Ramadas Madhavan
authors.initials: RM
authors.lastname: Nirmal
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene / Q000009:adverse effects / Q000031:analogs & derivatives*; D000818:Animals; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology; D063646:Carcinogenesis / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D002273:Carcinogens / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D049109:Cell Proliferation / Q000187:drug effects; D002610:Cheek / Q000473:pathology; D018890:Chemoprevention / Q000379:methods; D006224:Cricetinae; D044950:Flavanones / Q000494:pharmacology*; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008647:Mesocricetus; D009061:Mouth Mucosa / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D009062:Mouth Neoplasms / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D053758:Nanoparticles / Q000008:administration & dosage*; D010316:Particle Size; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D000975:Antioxidants; D002273:Carcinogens; D044950:Flavanones; D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53; C012929:7,12-dimethylbenz(a)anthracene 5,6-oxide; D015127:9,10-Dimethyl-1,2-benzanthracene; C005273:naringenin